AstraZeneca reported mixed phase 3 data for efzimfotase alfa in hypophosphatasia, with positive results in paediatric ...
AstraZeneca has reported positive results from the efzimfotase alfa Phase III clinical trial programme for hypophosphatasia ...
AstraZeneca Plc AZN released topline data from the Phase 3 program for efzimfotase alfa (ALXN1850) in the broad ...
The trial has an overall status of “Completed,” which means dosing and follow-up are finished. The study was first submitted to the registry on July 17, 2025, and the most recent update was filed on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results